Please login to the form below

Not currently logged in


This page shows the latest MyoKardia news and features for those working in and with pharma, biotech and healthcare.

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

As part of the merger, BMS has now gained the rights to MyoKardia’s investigational treatment mavacamten, which is currently in development for obstructive hypertrophic cardiomyopathy (HCM). ... The addition of MyoKardia’s pipeline cardiovascular

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice president of medical affairs. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a

  • Jonathan Fox leaves AstraZeneca for MyoKardia Jonathan Fox leaves AstraZeneca for MyoKardia

    Will lead programme to target genetic heart disease. MyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer. ... Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...